Genetic correlates of malignancy in TFE3 ‐rearranged PEComa : a series of 14 cases
Histopathology · 2025
DOI: 10.1111/his.15476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von David J Papke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Perivascular Epithelioid Cell Neoplasms, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bertarelli Rare Cancers Initiative.
Abstract (Originalsprache)
Aims
Perivascular epithelioid cell tumours (PEComas) show variable smooth muscle and melanocytic differentiation and mostly harbour mTOR pathway activation via TSC2 inactivation. Five–10% of sporadic PEComas instead harbour fusions involving TFE3 , an vmTOR pathway target. Malignancy in TSC2 / 1 ‐inactivated PEComa correlates with TP53 , RB1 or ATRX inactivation. Here, we investigated genetic correlates of malignancy in TFE3 ‐rearranged PEComa. Methods and Results Fourteen TFE3 ‐rearranged PEComas, confirmed by FISH and/or sequencing, occurred in 11 females (79%) and 3 males aged 9–64 years (median: 31.5 yr). Body sites were uterus (3 tumours), extremities (3), colon (2), nasal cavity (2), neck (1), retroperitoneum (1), bladder (1) and ovary (1). Nine tumours (64%) lacking cytologic atypia were diagnosed prospectively as benign, and five cytologically atypical tumours were diagnosed prospectively as malignant. By immunohistochemistry, tumours expressed SMA (6/13; 46%), HMB‐45 (5/13; 38%), desmin (3/13; 23%) and melan‐A (2/13; 15%), and not MITF (10 tumours), S‐100 (7), SOX10 (4), pan‐K (5) or EMA (3). By DNA sequencing, all nine benign tumours lacked complex copy number alterations (CNAs) or inactivation of TP53 , ATRX or RB1 . In contrast, three of four (75%) assessable malignant tumours showed complex CNAs, and only one of five malignant PEComas (20%) harboured TP53 inactivation. Among eight patients with follow‐up (57%), all four benign PEComas neither recurred nor metastasized (median: 5.0 yr; range: 3.3–8.1 yr), while all four malignant tumours metastasized.
Conclusions
We conclude that malignant TFE3 ‐rearranged PEComas frequently harbour complex CNAs, which could be of diagnostic utility. Malignant TFE3‐ rearranged PEComas lacked highly recurrent alterations in TP53 , RB1 or ATRX .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: David J Papke, Igor Odintsov, Navin R Mahadevan, John Hanna
Förderung
- NCI NIH HHS
- Bertarelli Rare Cancers Initiative
Zitieren
APA
Papke, D. J., Odintsov, I., Mahadevan, N. R., Fletcher, C. D., & Hanna, J. (2025). Genetic correlates of malignancy in TFE3 ‐rearranged PEComa : a series of 14 cases. Histopathology. https://doi.org/10.1111/his.15476
Vancouver
Papke DJ, Odintsov I, Mahadevan NR, Fletcher CD, Hanna J. Genetic correlates of malignancy in TFE3 ‐rearranged PEComa : a series of 14 cases. Histopathology. 2025. doi:10.1111/his.15476
BibTeX
@article{Papke2025,
author = {Papke, David J and Odintsov, Igor and Mahadevan, Navin R and Fletcher, Christopher Dm and Hanna, John},
title = {Genetic correlates of malignancy in TFE3 ‐rearranged PEComa : a series of 14 cases},
journal = {Histopathology},
year = {2025},
doi = {10.1111/his.15476}
}
EUVIMED